FCGR2B and glioblastoma: In the mouse GBM, anti-IGFBP2 also significantly decreased CD19+p-FcγRIIB+ B cells (Fig 4I and 4J, * p < 0.05) and increased the number of CD19+ B cells corresponding to p-FcγRIIB+ B cells (Fig 4K, * p < 0.05).